기준가
$18.49
운용 규모
$13.7M
보수율
-
배당수익률
0.00%
베타
2.12
통화
USD
| YTD | 1개월 | 3개월 | 1년 | 3년 | 5년 |
|---|---|---|---|---|---|
| +49.84% | +58.88% | +76.20% | +236.93% | +32.15% | -4.53% |
| 순위 | 종목코드 | 종목명 | 비중 |
|---|---|---|---|
| 1 | OGN | Organon & Co Ordinary Shares | 2.39% |
| 2 | CORT | Corcept Therapeutics Inc | 2.36% |
| 3 | LQDA | Liquidia Corp Ordinary Shares | 1.84% |
| 4 | AXSM | Axsome Therapeutics Inc | 1.69% |
| 5 | DFTX | Definium Therapeutics Inc Ordinary Shares | 1.49% |
| 6 | ELVN | Enliven Therapeutics Inc | 1.48% |
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
설정일: 2017-11-15